(Q54288887)

English

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. (English)

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Filippo Pietrantonio

2

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Antonia Martinetti

5

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Maria Di Bartolomeo

9

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Filippo de Braud

10

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Maria Grazia Daidone

11

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Vera Cappelletti

12

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Valeria Musella

object named as

Valeria Musella

1

0 references

object named as

Claudia Maggi

8

0 references

Elisa Sottotetti

object named as

Elisa Sottotetti

6

0 references

Roberto Iacovelli

4

object named as

Roberto Iacovelli

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

author name string

Eleonora Di Buduo

3

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Ilaria Bossi

7

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

language of work or name

0 references

publication date

4 March 2015

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

International Journal of Cancer

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

137

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

6

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

1467-1474

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Real-time liquid biopsy in cancer patients: fact or fiction?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Circulating tumor cells in colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Translational clinical trials: an entropy-based approach to sample size

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29493

21 January 2018

Identifiers

10.1002/IJC.29493

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

release_fy4xrlbb4nhtdnqiv7uukr6epi

1 reference

https://api.fatcat.wiki/v0/release/fy4xrlbb4nhtdnqiv7uukr6epi

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/25704501

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54288887&oldid=1844368897"